Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > AVNR > Summary

Avanir Pharmaceuticals
(AVNR)

1.73USD   Up0.02 (1.17%)   
At 2:30AM IST
 Avanir Pharmaceuticals (NGM:AVNR) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 1.73USD
Trade Time:2:30AM IST
Change:Up0.02 (1.17%)
Prev Close:1.71
Open:1.73
Bid:1.48 x 5000
Ask:1.75 x 1400
1y Target Est:8.90
Day's Range:1.67 - 1.76
52wk Range:0.25 - 4.09
Volume:596,228
Avg Vol (3m):569,594
Market Cap:143.88M
P/E (ttm):N/A
EPS (ttm):-0.28
Div & Yield:N/A (N/A%)
Add AVNR to Portfolio   Download Data

HEADLINES

 
•AVANIR PHARMACEUTICALS, INC. Financials - EDGAR Online Financials  - Fri, Feb 5
•Avanir Pharmaceuticals, Inc. F1Q10 (Qtr End 12/31/09) Earnings Call Transcript - Seeking Alpha  - Wed, Feb 3
•AVANIR to Present at the 12th Annual BIO CEO & Investor Conference - Business Wire  - Wed, Feb 3
•AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition - EDGAR Online  - Tue, Feb 2
•AVANIR Pharmaceuticals Announces Fiscal 2010 First Quarter Financial Results - Business Wire  - Tue, Feb 2
•Q1 2010 AVANIR Pharmaceuticals Earnings Release - Before Market Open - CCBN  - Tue, Feb 2
•Coverage initiated on Avanir Pharmaceuticals by Merriman - Briefing.com  - Fri, Jan 29
•AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 First Quarter Conference Call - Business Wire  - Tue, Jan 26
•Biotech Calendar: Upcoming FDA Dates - TheStreet.com  - Tue, Dec 15
•Sequenom, Avanir: Early Volume Plays - TheStreet.com  - Wed, Dec 9
» More Headlines for AVNR...

ANALYST

 
EPS Est (next year) (Sep-10) :-0.30
EPS Est (in 2 years) (Sep-11) :0.26
Avg Rec (current)*:1.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada.

» Full Company Profile